Lirum Therapeutics (Lirum Therapeutics) Accounts Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Lirum Therapeutics's accounts receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Lirum Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.20.

Lirum Therapeutics Accounts Receivable Historical Data

The historical data trend for Lirum Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Accounts Receivable Chart

Lirum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Receivable

Lirum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Accounts Receivable	-	-	-	-	-

Lirum Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Lirum Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Lirum Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Lirum Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Lirum Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(4.009	+	0.75 * 0	+	0.5 * 0	-	2.18
-	0	-	0)	/	9.270
=	0.20

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Lirum Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Lirum Therapeutics (Lirum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

590 Madison Avenue, 21st Floor, New York, NY, USA, 10022

Website

https://www.lirumtx.com

Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines